Kiniksa Pharmaceuticals International, plc (KNSA) – What Are Researchers Saying About This Stock?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $93.14.

A number of equities analysts recently issued reports on KNSA shares. The Goldman Sachs Group upped their price target on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Citigroup boosted their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th.

Insider Buying and Selling

In other news, Director G. Bradley Cole sold 3,673 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. The trade was a 23.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Michael Megna sold 4,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the transaction, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. The trade was a 13.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently bought and sold shares of KNSA. Curry Webb Wealth Management LLC bought a new position in Kiniksa Pharmaceuticals International in the 3rd quarter worth about $29,000. Allworth Financial LP raised its stake in shares of Kiniksa Pharmaceuticals International by 42.0% in the 2nd quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after acquiring an additional 134 shares in the last quarter. Nykredit A S bought a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $34,000. KBC Group NV acquired a new position in Kiniksa Pharmaceuticals International during the first quarter worth $34,000. Finally, USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International in the third quarter valued at about $69,000. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $76.73 on Tuesday. Kiniksa Pharmaceuticals International has a one year low of $35.20 and a one year high of $84.06. The stock has a 50-day moving average of $78.13 and a 200-day moving average of $65.07. The company has a market cap of $5.99 billion, a PE ratio of 79.10 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The firm had revenue of $243.60 million during the quarter, compared to analyst estimates of $226.49 million. Analysts expect that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.